Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991977 · ClinicalTrials.gov registry record · Phase 2
18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
A Phase 2 study of Malignant Glioma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT01991977: Completed Phase 2 study of Malignant Glioma, sponsored by Mayo Clinic.
NCT01991977 is a Phase 2 study of Malignant Glioma that has completed, run by Mayo Clinic. The registered enrollment target is 91 participants, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01991977, a Phase 2 study of Malignant Glioma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- RADIATION Intensity-Modulated Radiation Therapy
- PROCEDURE Diffusion Weighted Imaging
- PROCEDURE Perfusion Magnetic Resonance Imaging
- DRUG Fluorine F 18 Fluorodopa
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2013-12 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991977
The ClinicalTrials.gov registry entry for NCT01991977 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT01991977 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT01991977 about?
NCT01991977 is a clinical study titled "18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy". This phase II trial studies how well fluorine F 18 fluorodopa (18F-DOPA)-positron emission tomography (PET) works in finding tumors in patients with newly diagnosed gliomas undergoing radiation therapy. Comparing results of diagnostic procedures done before and during radiation therapy may help doct...
What is the current status of trial NCT01991977?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2013-12. Estimated completion is 2024-07-15.
What conditions does trial NCT01991977 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT01991977?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Intensity-Modulated Radiation Therapy (RADIATION), Diffusion Weighted Imaging (PROCEDURE), Perfusion Magnetic Resonance Imaging (PROCEDURE), Fluorine F 18 Fluorodopa (DRUG).
Who is sponsoring clinical trial NCT01991977?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01991977 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 2
-
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.